Important Topics in Treatment and Management of RA

Title:

Important Topics in Treatment and Management of RA

Topic: Rheumatology
Relevant Terms: Rheumatoid Arthritis
Primary Audience: Rheumatologists, Rheumatology Nurses
Launch Date: 26-Sep-13
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: 01-Oct-14

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Compare the safety profiles of current biologic disease-modifying antirheumatic drugs (DMARDs) commonly used for the treatment of RA
  2. Implement and/or optimize the utilization of target-based patient management within the next three months to standard patient care and optimize overall outcomes 
  3. Assess the clinical applicability of recently published and presented comparative effectiveness data regarding biologic therapies in rheumatoid arthritis 
  4. Review latest information from the EULAR congress pertaining to the management of patients with RA 

    Faculty

    Mark C. Genovese, MD
    Professor of Medicine
    Division of Immunology & Rheumatology
    Stanford University School of Medicine
    Palo Alto, CA
    Instructions on How to Receive Credit
    • Participants must review the materials on accreditation information, target audience, learning objectives, and disclosure information.
    • Complete the entire activity, pre/post-test and evaluation.
    • After passing the post-test, print out your electronic CE certificate.
    • In order to successfully complete this activity learners must achieve a minimum of 75% on the post-test.
    This activity is supported by unrestricted educational grants from Amgen and Genentech.

    This activity is sponsored by the Institute for Continuing Healthcare Education

    Release Date: September 26, 2013
    Expiration Date: October 1, 2014

     
    Accreditation Statements
    Physicians
    The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The Institute for Continuing Healthcare Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
     
    Disclosure
    Relationships are abbreviated as follows: E, Educational Planning Committee; G, Grant/research support recipient; A, Advisor/review panel member/educational planning committee; C, Consultant/Independent Contractor; SS, Stock shareholder; SB, Speaker bureau; PE, Promotional Event Talks; H, Honoraria; O, Other.

    Faculty
    Mark C. Genovese, MD 
    Stanford University School of Medicine
    Palto Alto, CA


    Dr. Genovese has disclosed the following relevant financial relationships in the past 12 months: AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Crescendo Pharmaceuticals, Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, and Vertex/A; Japan Tobacco, Principia Biopharma, Pharmacyclics/C; Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, and Vertex/G. 

    Medical Writer
    Kathy Holliman
    Donald Editorial Services, LLP
    Woodstown, NJ

    Ms. Holliman has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

    Peer Reviewer
    Stanford Peng, MD
     
    Virginia Mason Medical Center
    Seattle, WA


    Dr. Peng has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of this activity.

    Activity Development and Management Team
    Cathy Pagano, CCMEPAllison A. Muller, Pharm.D, D.ABATScott Kober, MBA, CCMEPApril Reynolds, MS, ELSSandra Davidson; and Megan Small are employees of the Institute and have no relationships to disclose.

    Off-label Product Disclosure
    This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 18.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
    Safari 4.0+ for Mac OSX 10.5 and above
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above

     

    For additional technical support, please send an email to msmall@iche.edu.

    General Disclosure and Copyright Statement
    The opinions expressed in this publication are those of the participating faculty and not those of the Institute for Continuing Healthcare Education (the Institute), Amgen, Genentech, or any manufacturers of products mentioned herein.

    This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional regarding diagnostic and treatment options of a specific patient's medical condition. In no event will the Institute be responsible for any decision made or action taken based upon the information provided in this activity.

    Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosages, and contraindications. This recommendation is particularly important for new or infrequently used products.

    Copyright 2013. Institute for Continuing Healthcare Education (the Institute). All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means electronic or mechanical—without first obtaining written permission from the Institute.
     
    The Institute reserves the right to cancel or modify the activity content, faculty, and activities if necessary.